Biotechnology entrepreneurs recalibrated in 2022 as their financing options narrowed, a reversal from years in which life-sciences startups were flush with capital. With just two weeks left in the year, U.S. biotechs had raked in $29.7 billion for 2022, compared with the record—$38.7 billion—deployed in all of 2021, according to market tracker PitchBook Data Inc.

While RNA therapeutics have the potential to potently modulate disease causing genes to treat patients with serious disorders, delivery of this therapeutic class to tissues outside of the liver remains a challenge.  Oligonucleotide therapeutics, such as short interfering RNA (siRNA), are rapidly cleared by the kidneys before they can reach the diseased tissue, and the […]

Antibody (Ab) therapeutics are the most prominent class of drugs today. Developed to deliver cytotoxic payloads to tumors, these therapies are evolving to provide new, next-generation conjugates and treat various diseases beyond cancer. “Among the emerging antibody drugs, those in the non-traditional formats are becoming more and more popular, such as bispecific antibodies and antibody-drug […]